Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Exploring chemotherapy-free induction treatment for patients with Ph+ ALL

Robin Foà • 11 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Dasatinib
GIMEMA LAL2116

Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discusses opportunities for a chemotherapy-free frontline induction treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Prof. Foà first discusses results from the GIMEMA LAL2116 trial (NCT02744768) evaluating the use of frontline dasatinib followed by blinatumomab in Ph+ ALL, and then goes on to discuss the importance of reducing the use of chemotherapy-based regimens in this disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Robin Foà

New frontiers in ALL - MRD for clinical practice
New frontiers in ALL - MRD for clinical practice
Robin Foà et al. • 29 Sep 2022
Novel treatment strategies in ALL
Novel treatment strategies in ALL
Nicholas Short et al. • 29 Sep 2022
Considerations for the implementation of novel therapies into ALL clinical practice
4:41
Considerations for the implementation of novel therapies into ALL clinical practice
Robin Foà • 15 Apr 2024
Are transplantation and chemotherapy still necessary for all patients with Ph+ ALL?
5:14
Are transplantation and chemotherapy still necessary for all patients with Ph+ ALL?
Robin Foà • 15 Apr 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals